Login to Your Account


AMSTERDAM – A combination of two Abbvie Inc. drugs, glecaprevir and pibrentasvir (G/P), helped 95 percent of noncirrhotic patients infected with the world's most common genotype of chronic HCV achieve undetectable levels of the virus in their blood at 12 weeks.

more »


Hoping to succeed where pharma giant Novartis AG failed in a late-stage trial, KPI Therapeutics Inc. is "working on closing out an investment round" to enable a phase II experiment with lead compound dalazatide in inclusion-body myositis (IBM), CEO Charles Magness told BioWorld Insight. "We hope to get that [financing] rolling in the summer-ish time frame," he said.

read more »

Our Habitat for All Things Science
Specific lead identified in the fight against TB

Novel analogues of a class of antibacterial compounds isolated from soil bacteria could lead to the development of urgently needed new treatments for tuberculosis (TB), according to the findings of a study led by Australian researchers at the University of Sydney.

Worldwide, TB causes more deaths than any other infectious disease including HIV/AIDs. According to the WHO, there were an estimated 10.4 million new cases of TB and 1.8 million deaths in 2015, with 60 percent of all new cases occurring in Asia.



Partners in Focus